Haddonfield NJ, September 1, 2018–Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics, today announced the appointment of Tina Garyantes, Ph.D., as Senior Vice President of Research and Development.
In her role at Linnaeus, Dr. Garyantes will be responsible for development of the Company’s pipeline of compounds, program leadership and regulatory affairs. She will report to the CEO, Patrick Mooney, M.D.
“Tina brings 25 years of drug discovery and development experience that will be exceptionally valuable to Linnaeus,” said Dr. Mooney. “She has a tremendous depth and breadth of expertise, and we are fortunate to have her nonclinical, scientific and clinical leadership as we advance LNS8801 through the necessary work to initiate phase 1 and 2 clinical studies of LNS8801 that should begin in 2019.”
Dr. Garyantes brings a mix of scientific leadership, business acumen, and a track record of innovation. She has broad therapeutic expertise based on strategic leadership roles in multiple therapeutic areas and project progression review across all therapeutic areas at Sanofi. She has managed cross-functional departments and led teams of well over 100 scientists for much of the past 25 years in the following fields: early pharmaceutical development, ADME, in vivo pharmacology, molecular biology, cell biology, automation, assay development, screening, medicinal chemistry, natural product chemistry, analytical chemistry, chemoinformatics, bioinformatics, scientific computing, safety, protein production, and compound management. Most recently, she was responsible for advancing Chromocell’s pain therapeutic from first synthesis into the clinic in 3 years while establishing a partnership with Astellas Pharmaceuticals for the single preclinical molecule with over $500 million in preclinical and clinical milestones. Prior to Chromocell, she was founder and CEO of MaxSAR, and served as a global discovery head at Sanofi. While at Merck, she invented and out-licensed a novel well-less 1536 “well” plate to Becton Dickenson that is currently sold commercially by Curiox. At Chiron Diagnostic, she co-developed and installed at the Mayo Clinic the first commercial laboratory instrument for fine structure analysis of DNA. She received her undergraduate degree from the University of Pennsylvania and her Ph.D. from the California Institute of Technology.
Linnaeus Therapeutics, Inc. is a privately held biopharmaceutical company focused on the development and commercialization of novel, small molecule oncology therapeutics that target a novel G protein-coupled receptor, known as GPER, or GPR30. The company was launched through the UPstart incubator at the University of Pennsylvania’s Penn Center for Innovation (PCI) Ventures. Its lead molecule, LNS8801, is in the final stages of preclinical development. The Company expects to begin its phase 1 clinical program in the summer of 2019. In addition to developing GPER agonists, Linnaeus is also currently focusing on developing small molecules that activate other G protein-coupled receptors to engage tumor-suppressive cellular signaling pathways.
Chief Executive Officer